Disruption of Hippo–YAP signaling has been confirmed to promote tumorigenesis in breast cancer [54, 55], ovarian cancer [56, 57], neurofibroma [58], and prostate cancer [59, 60]. Here, YAP1 is linked to prostate carcinoma.